Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1684

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1684
---
, and any equivalent regulatory authority in other countries, will agree with our
assessment of whether such extensions are available, and such authorities may refuse to grant extensions to such patents, or may grant
more limited extensions than requested. Moreover, the applicable time period or the scope of patent protection afforded could be less
than requested. If we are unable to obtain patent term extension or term of any such extension is less than requested, our competitors
may obtain approval of competing products following our patent expiration, and our business could be harmed. Changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the
scope of our patent protection.

The patent pending applications
for our product candidates are expected to expire on various dates. Upon the expiration, we will not be able to assert such licensed patent
rights against potential competitors, which would materially adversely affect our business, financial condition, results of operations
and prospects.

Risks Related to Ownership of our Securities

Sales of a substantial number of our securities
in the public market by our existing securityholders could cause the price of our Common Stock and Warrants to fall.

Sales of a substantial number
of shares of our Common Stock in the public market could occur at any time (after the expiration of any applicable lock-up period, assuming
the satisfaction of any applicable vesting conditions and subject to the beneficial ownership and stock exchange limitations described
herein). These sales, or the perception in the market that the holders of a large number of shares of our Common Stock intend to sell
shares, could increase the volatility of the market price of our Common Stock or result in a significant decline in the public trading
price of our Common Stock.

The resale, or expected or
potential resale, of a substantial number of shares of our Common Stock in the public market could adversely affect the market price for
our Common Stock and make it more difficult for you to sell your holdings at times and prices that you determine are appropriate. Accordingly,
the adverse market and price pressures resulting from an offering may continue for an extended period of time. Sales of substantial number
of such shares in the public market could adversely affect the market price of our Common Stock.

We have filed (in each case,
the share numbers set forth below have been adjusted for the Reverse Stock Split):

●a
                                            registration statement with the SEC for purposes of registering the resale from time to time
                                            of up to 2,100,000 Shares of Common Stock, which